Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15483449rdf:typepubmed:Citationlld:pubmed
pubmed-article:15483449lifeskim:mentionsumls-concept:C0032659lld:lifeskim
pubmed-article:15483449lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:15483449lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:15483449lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:15483449lifeskim:mentionsumls-concept:C0022658lld:lifeskim
pubmed-article:15483449lifeskim:mentionsumls-concept:C2003888lld:lifeskim
pubmed-article:15483449lifeskim:mentionsumls-concept:C0023779lld:lifeskim
pubmed-article:15483449lifeskim:mentionsumls-concept:C0360714lld:lifeskim
pubmed-article:15483449lifeskim:mentionsumls-concept:C0686904lld:lifeskim
pubmed-article:15483449lifeskim:mentionsumls-concept:C0814225lld:lifeskim
pubmed-article:15483449pubmed:issue6lld:pubmed
pubmed-article:15483449pubmed:dateCreated2004-10-14lld:pubmed
pubmed-article:15483449pubmed:abstractTextThis review outlines the limited information currently available on the effects of statins among patients with chronic kidney disease, and summarizes the ongoing randomized trials designed to address this question.lld:pubmed
pubmed-article:15483449pubmed:languageenglld:pubmed
pubmed-article:15483449pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15483449pubmed:citationSubsetIMlld:pubmed
pubmed-article:15483449pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15483449pubmed:statusMEDLINElld:pubmed
pubmed-article:15483449pubmed:monthNovlld:pubmed
pubmed-article:15483449pubmed:issn1062-4821lld:pubmed
pubmed-article:15483449pubmed:authorpubmed-author:BaigentColinClld:pubmed
pubmed-article:15483449pubmed:authorpubmed-author:LandrayMartin...lld:pubmed
pubmed-article:15483449pubmed:authorpubmed-author:WarrenMarionMlld:pubmed
pubmed-article:15483449pubmed:issnTypePrintlld:pubmed
pubmed-article:15483449pubmed:volume13lld:pubmed
pubmed-article:15483449pubmed:ownerNLMlld:pubmed
pubmed-article:15483449pubmed:authorsCompleteYlld:pubmed
pubmed-article:15483449pubmed:pagination601-5lld:pubmed
pubmed-article:15483449pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:15483449pubmed:meshHeadingpubmed-meshheading:15483449...lld:pubmed
pubmed-article:15483449pubmed:meshHeadingpubmed-meshheading:15483449...lld:pubmed
pubmed-article:15483449pubmed:meshHeadingpubmed-meshheading:15483449...lld:pubmed
pubmed-article:15483449pubmed:meshHeadingpubmed-meshheading:15483449...lld:pubmed
pubmed-article:15483449pubmed:meshHeadingpubmed-meshheading:15483449...lld:pubmed
pubmed-article:15483449pubmed:meshHeadingpubmed-meshheading:15483449...lld:pubmed
pubmed-article:15483449pubmed:year2004lld:pubmed
pubmed-article:15483449pubmed:articleTitleStatin therapy in kidney disease populations: potential benefits beyond lipid lowering and the need for clinical trials.lld:pubmed
pubmed-article:15483449pubmed:affiliationClinical Trial Service Unit and Epidemiological Studies Unit, Radcliffe Infirmary, Woodstock Road, Oxford, OX2 6HE, UK. colin.baigent@ctsu.ox.ac.uklld:pubmed
pubmed-article:15483449pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15483449pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15483449lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15483449lld:pubmed